Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

48.37 -1.24 (-2.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,569,089
Open 49.61
Bid (Size) 46.70 (100)
Ask (Size) 55.00 (2,000)
Prev. Close 49.61
Today's Range 48.21 - 50.40
52wk Range 25.16 - 55.67
Shares Outstanding 166,121,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Alkermes Q2 Earnings Call Highlights ↗
Alkermes (NASDAQ:ALKS) reported second-quarter 2026 revenue of $496 million, supported by growth across its proprietary product portfolio and the first full-quarter contribution from LUMRYZ following... 
Via MarketBeat
Topics Earnings
Alkermes (NASDAQ:ALKS) Reports Quality Earnings Beat but Stock Falls on Lack of Guidance ↗
Via Chartmill
Topics Earnings

Performance

YTD
+71.2%
+71.2%
1 Month
-12.4%
-12.4%
3 Month
+36.6%
+36.6%
6 Month
+44.2%
+44.2%
1 Year
+82.2%
+82.2%

More News

Read More
News headline image
Alkermes plc Reports Second Quarter 2026 Financial Results
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Report Second Quarter Financial Results on July 28, 2026
From Alkermes plc
Via Business Wire
Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss ↗
Via Chartmill
Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential ↗
Via Chartmill
News headline image
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
From Alkermes plc
Via Business Wire
News headline image
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
From Alkermes plc
Via Business Wire
News headline image
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears ↗
Via MarketBeat
News headline image
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
From Alkermes plc
Via Business Wire
News headline image
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
From Alkermes plc
Via Business Wire
News headline image
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
From Alkermes plc
Via Business Wire
News headline image
Alkermes (ALKS) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Alkermes plc Reports First Quarter 2026 Financial Results
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Report First Quarter Financial Results on May 5, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
From Alkermes plc
Via Business Wire
News headline image
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
From Alkermes plc
Via Business Wire
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
Via MarketMinute
News headline image
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
From Alkermes plc
Via Business Wire
News headline image
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
From Alkermes plc
Via Business Wire

Frequently Asked Questions

Is Alkermes plc - Ordinary Shares publicly traded?
Yes, Alkermes plc - Ordinary Shares is publicly traded.
What exchange does Alkermes plc - Ordinary Shares trade on?
Alkermes plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alkermes plc - Ordinary Shares?
The ticker symbol for Alkermes plc - Ordinary Shares is ALKS on the Nasdaq Stock Market
What is the current price of Alkermes plc - Ordinary Shares?
The current price of Alkermes plc - Ordinary Shares is 48.37
When was Alkermes plc - Ordinary Shares last traded?
The last trade of Alkermes plc - Ordinary Shares was at 08/06/26 04:00 PM ET
What is the market capitalization of Alkermes plc - Ordinary Shares?
The market capitalization of Alkermes plc - Ordinary Shares is 8.04B
How many shares of Alkermes plc - Ordinary Shares are outstanding?
Alkermes plc - Ordinary Shares has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.